Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Taiho Seals Trial Pact for Arcus Oncology Meds to Work with Gilead
Taiho Pharmaceutical said on May 18 that it has sealed a three-way clinical trial agreement to collaborate with Gilead Sciences for the development of immuno-oncology treatments in-licensed from Arcus Biosciences. The Japanese company struck a license and option agreement with…
To read the full story
Related Article
- Another Global PIII Shuttered for Arcus-Partnered TIGIT Combo: Taiho
April 22, 2026
- Global PIII Trial Halted for Arcus-Partnered TIGIT Drug: Taiho
December 16, 2025
- Taiho Secures Japan, Asian Rights to Arcus’ HIF-2α Inhibitor Casdatifan
October 21, 2025
- Taiho Bags Japan, Asian Rights to Arcus’ CD73 Inhibitor
July 10, 2024
- Taiho Exercises Option to Grab Arcus’ Anti-TIGIT Antibodies
December 1, 2021
- Taiho Gains Japan/Asian Rights to Arcus’ Anti-PD-1 Antibody
February 28, 2020
- Taiho Exercises Option to Gain Asian Rights to Arcus’ I/O Candidate
July 17, 2018
- Taiho Gets Option for Arcus’ Immuno-Oncology Portfolio in Japan, Asia
September 21, 2017
BUSINESS
- MSD Launches RSV Antibody Enflonsia in Japan without NHI Listing
August 24, 2026
- Sumitomo Pharma Eyes Global Position as Adjuvant Supplier
August 24, 2026
- Oncolys’ Oncolytic Virus Telomelysin Hits Japan Market
August 24, 2026
- Sobi’s Still’s Disease Drug Kineret Now Available in Japan
August 24, 2026
- MSD Files Welireg-Keytruda Combo in Japan for Adjuvant RCC
August 24, 2026
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…